Recommended by more than 40 happy clients

“BioNixus delivered payer and hospital research across the GCC with the depth we needed for launch sequencing. Their bilingual field teams understood FDA-aligned access frameworks and DHA dynamics, and the executive readout connected directly to our pricing and access milestones.”

“We needed credible KOL mapping and physician insight across Egypt and the Gulf in weeks, not months. BioNixus recruited scarce specialists quickly and translated field findings into a clear EMEA expansion narrative our board could act on.”

“From survey design through to final deliverables, the team maintained rigorous sample governance and GDPR-aligned protocols. The quantitative physician work in Egypt gave us segment-level evidence we could not have sourced through a generalist agency.”

“BioNixus ran a multi-wave physician survey in Saudi Arabia with transparent methodology notes and responsive project leadership. Their understanding of local clinical practice made the qualitative follow-ups especially valuable for our medical affairs team.”

“We compared several vendors for a three-market launch-readiness programme. BioNixus stood out for senior-led execution, realistic timelines, and decision-ready outputs — not just data tables. They have become a trusted partner for our MENA portfolio work.”

“BioNixus ran payer and hospital stakeholder research ahead of our US launch — covering Medicare Advantage dynamics, specialty pharmacy routing, and community oncologist adoption barriers. The team translated complex access findings into a launch narrative our US commercial and policy leads could execute against immediately.”

“We needed hospital procurement and cath-lab physician insight across the Northeast and Midwest for a next-generation device portfolio. BioNixus designed a mixed-methods programme with IDN budget-holder interviews and proceduralist surveys — delivering segment-level evidence our US sales and clinical teams still reference in QBRs.”

“BioNixus harmonised a Canada–US physician and patient journey study for our rare disease asset, navigating PCPA and provincial formulary nuances alongside US payer archetypes. Their North America field network recruited scarce specialists faster than our previous global panel vendor.”

“BioNixus supported our NICE and SMC evidence planning with UK payer, pharmacist, and hospital pharmacy research that went beyond syndicated data. The deliverables connected HTA stakeholder priorities to our value dossier structure — exactly the kind of decision-ready work we expect from a healthcare-native partner.”

“For our EU MDR transition portfolio, BioNixus mapped German hospital budget holders, OR directors, and procurement committees across tertiary centres. Their bilingual moderation and G-BA-aware framing helped us prioritise which clinical endpoints resonated with Kassen and private pathways alike.”

“BioNixus executed a France-first physician and payer study aligned with HAS transparency expectations — from questionnaire localisation through to executive synthesis in Paris. The work informed our pricing corridor and medical affairs narrative ahead of CEPS discussions.”

“We commissioned hospital laboratory and radiology pathway research across Italy and Spain for a diagnostics platform rollout. BioNixus recruited hard-to-reach hospital decision-makers, respected GDPR field protocols, and delivered comparable G5 market reads our EMEA leadership could benchmark side by side.”

“BioNixus ran surgeon and hospital administrator research in São Paulo and Rio for our ANVISA-registered implant portfolio — blending private hospital procurement dynamics with SUS-relevant clinical opinion leader mapping. Their Portuguese field team understood Brazilian orthopaedic practice in a way generic LATAM vendors did not.”

“BioNixus delivered a harmonised physician and payer programme across Mexico, Colombia, and Brazil for our immunology franchise — including bilingual moderation, local IRB-aware recruitment, and a single regional readout our LATAM brand team used for 2026 access planning.”